Fortress Biotech (Fortress Biotech) Gross Margin % : 69.84% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Fortress Biotech's Gross Profit for the three months ended in Dec. 2023 was $13.93 Mil. Fortress Biotech's Revenue for the three months ended in Dec. 2023 was $19.95 Mil. Therefore, Fortress Biotech's Gross Margin % for the quarter that ended in Dec. 2023 was 69.84%.

Warning Sign:

Fortress Biotech Inc gross margin has been in long-term decline. The average rate of decline per year is -3.9%.

The historical rank and industry rank for Fortress Biotech's Gross Margin % or its related term are showing as below:

FBIO' s Gross Margin % Range Over the Past 10 Years
Min: 31.13 Med: 68.22 Max: 78.79
Current: 68.46

During the past 13 years, the highest Gross Margin % of Fortress Biotech was 78.79%. The lowest was 31.13%. And the median was 68.22%.

FBIO's Gross Margin % is ranked better than
59.73% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs FBIO: 68.46

Fortress Biotech had a gross margin of 69.84% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Fortress Biotech was -3.90% per year.

Fortress Biotech Gross Margin % Historical Data

The historical data trend for Fortress Biotech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Gross Margin % Chart

Fortress Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

71.25

67.99

53.36

59.37

68.45

Fortress Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															52.95	48.11	55.33	81.50	69.84

Competitive Comparison of Fortress Biotech's Gross Margin %

For the Biotechnology subindustry, Fortress Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortress Biotech's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Gross Margin % falls into.

Fortress Biotech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Fortress Biotech's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	57.9	/	84.513
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(84.513 - 26.66)	/	84.513
	=	68.45 %

Fortress Biotech's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	13.9	/	19.946
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(19.946 - 6.015)	/	19.946
	=	69.84 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Fortress Biotech (NAS:FBIO) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Fortress Biotech had a gross margin of 69.84% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Fortress Biotech Gross Margin % Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortress Biotech (Fortress Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

FBIOP.PFD:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Executives

Rosenwald Lindsay A Md	director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN	375 PARK AVE, NEW YORK NY 10152
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin	officer: Chief Financial Officer	C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein	director	C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter	officer: Chief Financial Officer	95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky	director	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein	director	750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss	director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN	750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell	director	365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey	director	3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz	director	C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos	officer: SVP, Biologics Operations	C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan	other: Former Chief Medical Officer	C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett	director	ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803